Denali Therapeutics
Denali Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$422 million. The diluted share count rose 5.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Denali Therapeutics does
Denali Therapeutics is a drug developer with no approved product. It works on a problem in medicine: the blood-brain barrier, a lining that protects the brain but also keeps most medicines out. Denali built its own delivery technology, called the TransportVehicle, which is designed to carry large-molecule drugs such as enzymes, antibodies and oligonucleotides across that barrier.
Its most advanced program, tividenofusp alfa, is for Hunter syndrome (MPS II), a rare inherited disease. The FDA is reviewing its license application under priority review, and the company has a target decision date of April 5, 2026. Its other programs include candidates for Sanfilippo syndrome type A and for a form of frontotemporal dementia, and it aims at common diseases such as Alzheimer's and Parkinson's.
Denali has no product revenue. It says it has made preparations to sell a medicine if it is approved, and it runs its own manufacturing facility.
Its biggest risks, as it describes them
- It has no approved products and may never become profitable.
- It depends heavily on its TransportVehicle technology and the programs in its pipeline.
- Its drugs use novel technology, so time and cost are hard to predict.
- Clinical trials may be delayed, or show side effects or fail to show benefit.
- It may fail to manufacture its candidates or to build sales and marketing.
Income statement
Denali Therapeutics lost money in fiscal 2025: a net loss of $512 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 865 | 1,336 | 1,034 | 832 | 868 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 2.4x | 3.8x | 13.7x | 8.5x | 9.2x |
| Quick ratio | 2.4x | 3.8x | 13.7x | 8.5x | 9.2x |
Cash flow
Projections
Project Denali Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Denali Therapeutics says to expect
- Fourth quarter 2026: net product revenue
Fourth-quarter 2026 net product revenue is expected to be $30.0 million to $32.0 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Denali Therapeutics shares on the open market, and 4 insiders sold $1.3 million, $326,811 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Peter Scott ChinChief Medical Officer | Sold | 1,654 | $22.29 | $36,868 | Form 4 |
| Sep 2, 2026 | Nancy ThornberryDirector | Sold plan | 11,439 | $22.90 | $261,929 | Form 4 |
| Sep 1, 2026 | Alexander O. SchuthCOFO and Secretary | Sold plan | 2,768 | $23.44 | $64,882 | Form 4 |
| Aug 11, 2026 | Alexander O. SchuthCOFO and Secretary | Sold | 2,857 | $25.07 | $71,625 | Form 4 |
| Jan 6, 2026 | Ryan J. WattsPresident and CEO, Director | Sold | 35,198 | $16.50 | $580,767 | Form 4 |
| Jan 6, 2026 | Alexander O. SchuthCOFO and Secretary | Sold | 17,218 | $16.50 | $284,097 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 92.5% | — | — |
| Altman Z'' | 10.11 | 6.54 | 3.62 |
| Accruals ratio | 16.3% | −5.9% | −7.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Denali Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics | FY25 | — | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 129 | 27 | 336 | 49 | 108 | 330 | 0 | 0 |
| Revenue growth | — | — | — | −79.3% | 1,158.2% | −85.5% | 122.9% | 204.7% | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 76 | 74 | 143 | 193 | 213 | 265 | 359 | 424 | 396 | 419 |
| Operating income | −87 | −90 | −46 | −213 | 63 | −296 | −341 | −197 | −487 | −555 |
| Net income | −87 | −88 | −36 | −198 | 71 | −291 | −326 | −145 | −423 | −512 |
| Diluted EPS (US$) | −13.49 | −5.89 | −0.39 | −2.07 | 0.63 | −2.39 | −2.60 | −1.06 | −2.57 | −2.97 |
| Diluted shares (millions) | 6 | 15 | 93 | 96 | 113 | 122 | 126 | 137 | 164 | 173 |
| Cash flow | ||||||||||
| Cash from operations | −72 | −77 | 50 | −152 | 416 | −211 | −245 | −358 | −348 | −413 |
| Capital expenditure | 6 | 3 | 3 | 18 | 3 | 8 | 18 | 13 | 16 | 10 |
| Free cash flow | −78 | −80 | 47 | −170 | 413 | −220 | −263 | −371 | −364 | −422 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 19 | 38 | 50 | 85 | 100 | 108 | 103 | 100 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 40 | 406 | 464 | 415 | 1,470 | 865 | 1,336 | 1,034 | 832 | 868 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | — | 487 | 662 | 553 | 1,604 | 1,404 | 1,460 | 1,154 | 1,374 | 1,145 |
| Total liabilities | — | 21 | 115 | 158 | 454 | 442 | 418 | 123 | 144 | 131 |
| Shareholders' equity | −94 | 466 | 547 | 395 | 1,150 | 962 | 1,042 | 1,031 | 1,230 | 1,014 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −35.9% | −799.1% | 18.7% | −607.8% | −314.2% | −59.5% | — | — |
| Net margin | — | — | −28.1% | −740.7% | 21.2% | −597.1% | −300.6% | −43.9% | — | — |
| Free cash flow margin | — | — | 36.2% | −635.3% | 123.1% | −451.9% | −242.1% | −112.2% | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | −714.7% | 1,281.2% | −537.4% | −119.2% | 92.5% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −7.2% | −42.0% | 9.2% | −27.5% | −32.5% | −14.0% | −37.4% | −45.7% |
| Return on assets | — | — | −6.3% | −32.5% | 6.6% | −19.3% | −22.8% | −11.1% | −33.5% | −40.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |